SanBio Co Ltd

8.2500-2.1700-20.83%Vol 5001Y Perf -56.81%
Dec 7th, 2021 14:05
BID0.0000 ASK0.0000
Open8.2500 Previous Close10.420
Pre-Market- After-Market-
 - -%  - -
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     45.37
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.00 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha0.03 Standard Deviation0.26
Beta-0.21 

Today's Price Range

8.25008.2500

52W Range

8.250016.750

5 Year PE Ratio Range

-45.200-39.600

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-20.83%
1 Month
-20.83%
3 Months
-29.18%
6 Months
-41.36%
1 Year
-56.81%
3 Years
-89.69%
5 Years
-32.93%
10 Years
0.00%

TickerPriceChg.Chg.%
SNBIF8.2500-2.1700-20.83
AAPL174.603.42002.00
GOOG2 965.024.29000.14
MSFT332.80-2.1200-0.63
XOM62.490.22000.35
WFC49.46-0.7900-1.57
JNJ163.760.40000.24
FB331.578.76002.71
GE98.591.04001.07
JPM160.43-2.1400-1.32
Financial StrengthValueIndustryS&P 500US Markets
4.70
5.10
0.29
0.67
-43.60
Leverage Ratio 1.70
ProfitabilityValueIndustryS&P 500US Markets
-
-29 144.10
-29 144.10
-746.20
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume500
Shares Outstanding0
Shares Float51.79M
Trades Count1
Dollar Volume4.13K
Avg. Volume1.33K
Avg. Weekly Volume2.22K
Avg. Monthly Volume1.27K
Avg. Quarterly Volume1.80K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

SanBio Co Ltd

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

CEO:

Telephone: +81 362643481

Address: 8-1 Street Luke Tower 28th Floor, Tokyo 104-0044, , JPN

Number of employees: 43

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

0%100%

Bearish Bullish

38%62%

Bearish Bullish

67%33%

News